Novacyt Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Lyn Rees

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO

Lyn Rees (50 yo)

no data

Tenure

Mr. Lyn Dafydd Rees serves as Executive Director at Novacyt S. A. since September 2023 and serves as its Chief Executive Officer since May 01, 2024. He serves as Non-Executive Director at MyHealthChecked P...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Lyn Rees	CEO & Executive Director	no data	no data	no data
Steve Gibson	CFO & Director	less than a year	no data	no data
Bryan Close	Chief Operations Officer	2.3yrs	no data	no data
Mandy Cowling	Corporate & Investor Relations Manager	no data	no data	no data
David Franks	Chief Human Resources Officer	3.1yrs	no data	no data
Paul Oladimeji	Group Head of R&D	no data	no data	no data

1.3yrs

Average Tenure

Experienced Management: NCYT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Lyn Rees	CEO & Executive Director	less than a year	no data	no data
Steve Gibson	CFO & Director	less than a year	no data	no data
John Brown	Non-Executive Director	less than a year	no data	no data
Andrew John Heath	Independent Senior Non-Executive Director	8.9yrs	UK£49.40k	0.028% £ 13.5k
Juliet Thompson	Independent Non-Executive Director	6.9yrs	UK£49.40k	no data
Jean-Pierre Crinelli	Independent Non-Executive Director	no data	UK£33.69k	0.048% £ 22.9k
David Gardner	Member of Scientific Committee	no data	no data	no data
Marco Zonta	Member of Scientific Committee	no data	no data	no data
Isabelle Cartier	Member of Scientific Committee	no data	no data	no data
Geneviève Bourg-Heckly	Member of Scientific Committee	no data	no data	no data
James Wakefield	Independent Non-Executive Chairman of the Board	10.3yrs	UK£128.33k	0.062% £ 29.6k

3.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: NCYT's board of directors are considered experienced (3.8 years average tenure).

Novacyt Management

Management criteria checks 1/4

Key information

Recent management updates

Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Novacyt Announces Step Down of David Allmond as Member of the Board

Novacyt S.A., Annual General Meeting, Jun 21, 2022

CEO & Director recently bought UK£100k worth of stock

Recent updates

Novacyt S.A. Notes DHSC Application for Summary Judgment Dismissed

New minor risk - Share price stability

New minor risk - Financial data availability

Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024

First half 2023 earnings released: UK£0.12 loss per share (vs UK£0.071 loss in 1H 2022)

New major risk - Revenue and earnings growth

Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023

Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023

New minor risk - Share price stability

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Full year 2022 earnings released: UK£0.31 loss per share (vs UK£0.14 loss in FY 2021)

Now 20% undervalued after recent price drop

Novacyt S.A. to Report Fiscal Year 2022 Results on Apr 24, 2023

Now 21% undervalued after recent price drop

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Novacyt Announces Step Down of David Allmond as Member of the Board

Novacyt Announces Approval of genesig® SARS-CoV-2 Winterplex® 3 Gene Assay Panel in the UK Under CTDA Legislation

Now 22% undervalued after recent price drop

First half 2022 earnings released: UK£0.07 loss per share (vs UK£0.18 loss in 1H 2021)

Novacyt S.A. Provides Group Financial Guidance for the Third Quarter and Year-To-Date Ended September 2022 and Fourth Quarter of 2022

Novacyt S.A. to Report First Half, 2022 Results on Sep 29, 2022

Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays

Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay

Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK

Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeypox Assay in Response to the Recent Outbreak of the Virus in Non-Endemic Countries

Novacyt S.A., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings released: UK£0.14 loss per share (vs UK£1.94 profit in FY 2020)

Price target decreased to UK£4.10

Novacyt S.A. Provides Update on DHSC Dispute

Novacyt Announces Approval of COVID-19 Test Under CTDA Legislation

CEO & Director recently bought UK£100k worth of stock

Novacyt S.A. Announces Approval of the First Direct-To-PCR Covid-19 Test in the UK Under CTDA Legislation

Novacyt S.A. to Report Fiscal Year 2021 Results on Apr 25, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new directors

Price target decreased to UK£5.20

Investor sentiment improved over the past week

Novacyt S.A. Reiterate Revenue Guidance for the Full Year

Full year 2020 earnings released

Novacyt S.A. Provides Sales Guidance for the Full Year 2021

Novacyt S.A. Announces the Launch of Two New Polymerase Chain Reaction Assays, Expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 Variant Detection Portfolios

Novacyt S.A. Announces Launch of VersaLab™ Portable

Investor sentiment deteriorated over the past week

Novacyt S.A. Announces Inclusion of SNPsig SARS-CoV-2 PCR Genotyping Portfolio in the NHS England Framework and Expansion of SNPsig Product Range

Investor sentiment improved over the past week

Novacyt S.A. Provides Earnings Guidance for the Year 2021

Investor sentiment deteriorated over the past week

New 90-day low: UK£6.84

Investor sentiment deteriorated over the past week

Novacyt S.A. Announces Launch of PCR Genotyping Assay Portfolio to Detect Covid-19 Variants

New 90-day high: UK£11.26

Investor sentiment improved over the past week

Novacyt S.A. Announces Board Changes

Novacyt S.A. Appoints James McCarthy as Chief Financial Officer

Novacyt S.A. Announces the Development of Three Tests for New Strains of COVID-19 and Avian Influenza

Investor sentiment improved over the past week

CEO & Director recently bought UK£497k worth of stock

Market pulls back on stock over the past week

Market pulls back on stock over the past week

Market bids up stock over the past week

Market pulls back on stock over the past week

New 90-day high: UK£9.55

Market bids up stock over the past week

Novacyt S.A. (ENXTPA:ALNOV) acquired IT-IS International Ltd. for £12 million.

Novacyt Signs a New Supply Contract with the UK Department of Health and Social Care

New 90-day high: UK£5.80

Novacyt S.A. Announces Launch of COVID-19 Antibody Test